4-Hydroxytamoxifen(Afimoxifene)

Name: 4-Hydroxytamoxifen(Afimoxifene)
Brand: Selleck Chemicals
SKU: S7827
Rating: 5 (7 reviews)

For research use only.

Catalog No.S7827 Synonyms: Afimoxifene

7 publications

4-Hydroxytamoxifen(Afimoxifene) Chemical Structure

CAS No. 68392-35-8

4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Selleck's 4-Hydroxytamoxifen(Afimoxifene) has been cited by 7 publications

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01174-z

PubMed: 33257837 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28910

PubMed: 31141164 ( click the link to review the publication )

Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

1 Customer Review

CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen(Afimoxifene) purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description

In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes^[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants ^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MCF7 cells	NGHrRoJRem:uaX\ldoF1cW:wIHHzd4F6			M1rFe2lvcGmkaYTpc44hd2ZiZYP0do9o\W5vc4TpcZVt[XSnZDDNR2YuPyClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OC53IH7N	NHnQN5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97NUS4PFE4Lz57NUS4PFE4RC:jPh?=
MCF7	MWjGeY5kfGmxbjDhd5NigQ>?			MXPF[oZm[3SrdnWg[I9{\SCob4KgX\|NJZS1iZYP0doFlcW:uIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCPQ1[tO{Bk\WyuczygSWM2OCB;IECuNFAxODNizszNMi=>	NGPWfXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5OlgyLz5{N{[5OlgyRC:jPh?=
MCF7	NWe5cIZNTnWwY4Tpc44h[XO\|YYm=		NYmw[Wg6PCCqcoO=	M4jtW2lv\HWldHnvckBw\iCHUnHsdIhiKGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIF3DSlch[2WubIOgbY4heGinbn;sJJJm\CCocnXlJHJRVUlibXXkbZVuKGOxboThbY5qdmdiNTWgZ4hiemOxYXyg[IV5fHKjbj30doVifGWmIF\CV{BqdmO3YnH0[YQh\m:{IESgbJJ{KGK7IGPQNUBidmRiYX70bU1GWiC{YXLibZQhdW:wb3PvcI5idCCjboTpZo9lgSCkYYPl[EBqdi2lZXzsJHdme3Sncn6gZZN{[XluIFHjeIl3cXS7IE2gNE4xODBzIN88UU4>	M1P3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEi2OlI3Lz5\|MEC4OlYzPjxxYU6=
MCF7	NH63PZVHfW6ldHnvckBie3OjeR?=			NV\iO4h[TW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6\|dDDNR2YuPyCkcnXhd5QhfHWvb4KgZ4VtdHNidYPpcochVUOILUegZZN{[XluIFXDOVAhRSByLkCwNFEzKM7:TT6=	NY\4T\|k6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4NlU6OzVpPkGyPFI2QTN3PD;hQi=>
MCF7	NX;UNG9bSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NVzxUmlxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzMEBKSzVyIE2gNE4xODB3IN88UU4>	M4HlN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC1Nlg3Lz5{MkSwOVI5PjxxYU6=
MCF7	NELGSllCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NV6z[lJtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzMEBKSzVyIE2gNE4xODB3M{eg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{CxNkc,OjZ2MEewNVI9N2F-
MCF	NY\ORWw1TnWwY4Tpc44h[XO\|YYm=			MUjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KHC{b3fld5Rmem:wZTDy[YNmeHSxcjDpckBpfW2jbjDNR2Yh[2WubIOgZZN{\XO\|ZXSgZZMh\XO2cnHkbY9tNWmwZIXj[YQhemWlZYD0c5IhemW\|cH;ud4UtKEmFNUCgQUAxNjByMEe5OFMh\|ryPLh?=	NELC[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwO\|AyOid-Mk[0NFcxOTJ:L3G+
Ishikawa endometrial cells	MUTGeY5kfGmxbjDhd5NigQ>?			M17wbGFod26rc4SgZYN1cX[rdImgZZMh[WytYXzpcoUheGixc4DoZZRie2ViaX7keYN1cW:wIHnuJGl{cGmtYYfhJIVv\G:vZYTybYFtKGOnbHzzJINwdXCjcnXkJJRwKEV{LDDFR\|UxKD1iMD6wNFA5KM7:TT6=	Mm\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV\|OECyNFgoRjF3M{iwNlA5RC:jPh?=
MCF7	NXPNc3hjTnWwY4Tpc44h[XO\|YYm=			MUXJcohq[mm2aX;uJI9nKGW\|dILv[4VvNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDNR2YuPyCkcnXhd5Qh[2GwY3XyJINmdGy\|LDDJR\|UxKD1iMD6wNFEyPyEQvF2u	NIrNcXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97MUW0PVY{Lz57MUW0PVY{RC:jPh?=
MCF7	Mn\rSpVv[3Srb36gZZN{[Xl?		MVyyOEBpenN?	M2O1WGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWLhcJBp[SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0do9o\W5vaX7keYNm\CC2cnHud4NzcXC2aX;uJJBz\WmwY4XiZZRm\CCxdnXycolocHRiZn;scI94\WRiYomg[ZN1em:pZX6gZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IHT1ZYwhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNFMh\|ryPLh?=	NXXjW\|hXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPVY{QThpPkK4Nlk3Ozl6PD;hQi=>
Rosetta 2 DE3	M1H0V2Z2dmO2aX;uJIF{e2G7		MVWxJIhz	M4LhbWRqe3CuYXPlcYVvfCCxZjDbN2heNWW\|dILh[IlwdCCocn;tJJJm[2:vYnnuZY51KGi3bXHuJG4ufGW{bXnuZYwhUGm\|LYTh[4dm\CCHUnHsdIhiKEyERDDoZZJjd3KrbnegR\|M5OVNxQ{SxO3MwSzV\|MGOgcZV1[W62IHX4dJJme3OnZDDpckBTd3OndIThJFIhTEV\|IHPvcZBmfGWwdDDj[YxteyCjZoTldkAyKGi{IHL5JHNRSSCkaX7kbY5oKGG\|c3H5MEBKSzVyIE2gNE4xODRizszNMi=>	NHTacGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK5OlM6QCd-MkiyPVY{QTh:L3G+
insect cells	MlrwSpVv[3Srb36gZZN{[Xl?			NYHFRmFOUW6qaXLpeIlwdiCxZjDmcJVwem2xbnWgSXMzKGe{ZXXuJIJqdmSrbnegeI8hemWlb33ibY5idnRiZoXscEBt\W6pdHigbJVu[W5iRWLhcJBp[SCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjByNkK5JO69VS5?	NWPVcmZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|UzOTRpPkK4O\|M2OjF2PD;hQi=>
MCF-7-2a	M1\BZ2Z2dmO2aX;uJIF{e2G7			NUOwVoFKUW6qaXLpeIlwdiCxZjDld5Rz[WSrb3ygbY5lfWOnZDDld5Rzd2enbjDy[YNmeHSxcjD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDpckBOS0ZvNz2yZUBk\WyuczygTWM2OCB;IECuNFA4KM7:TT6=	NHW0eVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[3NlI1QSd-MUK2O\|IzPDl:L3G+
MCF7	M3LhdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MknyNlQhcHK\|	MnL2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkCwPFUh\|ryPLh?=	M3rxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkeyNlU3Lz5zOEK3NlI2PjxxYU6=
MCF7	NFT2WG5HfW6ldHnvckBie3OjeR?=			NUPQcYhZUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgUWNHNTdiYoLlZZN1KHS3bX;yJINmdGy\|IIXzbY5oKE2FRj23JIF{e2G7LDDJR\|UxKD1iMD6wNFg2KM7:TT6=	NFO5ZWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkiyOVk{PSd-MUK4NlU6OzV:L3G+
Ishikawa cells	NHG2XIxHfW6ldHnvckBie3OjeR?=		MXO3NkBpenN?	NHvlUmpCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHXzeJJw\2WwIILlZ4VxfG:{IHHsdIhiN2KndHGgbY4hcHWvYX6gTZNpcWujd3GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGua3HsbY5mKHCqb4PwbIF1[XOnIHHzd4F6NCCLQ{WwJF0hOC5yMTFOwG0v	Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5N\|EoRjJ6NEK2PVMyRC:jPh?=
insect cells	MXTGeY5kfGmxbjDhd5NigQ>?			M4HtSWRqe3CuYXPlcYVvfCCxZjDmcJVwemW\|Y3XpckBt[WKnbHXkJIV{fHKjZHnvcEBnem:vIHj1cYFvKHKnY3;tZolv[W62IFXSZoV1[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh\|NUG3Okc,OTh6M{WxO\|Y9N2F-
MCF7	NYK1dYJ2S3m2b4TvfIlkcXS7IHHzd4F6		NXHBTIdUPSCmYYnz	M4HxSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOUBl[Xm\|LDDJR\|UxKD1iMD6wNlkyKM7:TT6=	NYnCW5VWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OlQ6OjhpPkKzPFY1QTJ6PD;hQi=>
GT1-7	M{n3WmZ2dmO2aX;uJIF{e2G7		NXHFNZU2OjBidH:gNlQhcHK\|	MlrWRY51[WexbnnzeEBi[3Srdnn0fUBifCCnc4Tyc4dmdiC{ZXPldJRweiCrbjDtc5V{\SCJVEGtO{Bk\WyuczDoZZJjd3KrbnegZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKDF5YnX0ZU1me3S{YXTpc4whcW6mdXPl[EBz\XOyb37z[UBu\WG\|dYLl[EBi\nSncjCyNEB1dyB{NDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOzN{IN88UU4>	MmLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MECyN\|koRjJ6NECwNlM6RC:jPh?=
insect cells	MnrFSpVv[3Srb36gZZN{[Xl?			MWfEbZNxdGGlZX3lcpQhd2ZiZnz1c5Jme2OnaX6gcIFj\WynZDDld5Rz[WSrb3yg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCHUnHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigSxiSVO1NEA:KDBwMESg{txONg>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh\|NUG3Okc,OTh6M{WxO\|Y9N2F-
HEK293	MoftSpVv[3Srb36gZZN{[Xl?		NED5NYk{OCCvaX7z	MX7Jcohq[mm2aX;uJI9nKEeIUD30ZYdo\WRiaIXtZY4hWEyGMjDlfJBz\XO\|ZXSgbY4hcHWvYX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJJBpd3OyaHH0bYR6dGK3dHHuc4wuY2R7XTDwdo9lfWO2aX;uJIFnfGW{IEOwJI1qdnNiYomgcYF{eyC\|cHXjeJJwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4xPDRizszNMi=>	M1nl[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUO2PVc2Lz5zOUGzOlk4PTxxYU6=
HEK293	MYTGeY5kfGmxbjDhd5NigQ>?		MUexJIhz	M{XneGFvfGGpb37pd5Qh[WO2aY\peJkh[XRicnXjc41jcW6jboSgbJVu[W5iRWLhcJBp[SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQhYU[SLX\1d4VlKFOUQ{GgZ49i[3SrdnH0c5IhemWlcoXpeI1mdnRibXXhd5Vz\WRiYX\0[ZIhOSCqcjDpckBxemW\|ZX7j[UBw\iCFb3Xs[Y51\XKjennu[UBJKGK7IFLSSXQh[XO\|YYmsJGlEPTBiPTCwMlA4KM7:TT6=	MoDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	NYniclZOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXTyVJdsPzJiaILz	MmDDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcjDk[ZBmdmSnboSgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNFch\|ryPLh?=	M2HBRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEO1NVc3Lz5zOEizOVE4PjxxYU6=
MCF7	M1vUVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYG3NkBpenN?	M17reWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWgZZN{[XluIFfJOVAhRSByLkGwO{DPxE1w	NIK5O3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ezOVgzQSd-MkO3N\|U5Ojl:L3G+
MCF7	NFTIUpRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH7mS2o4OiCqcoO=	NHrkNI9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVTNWSncHXu[IVvfCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjFzIN88UU4>	NVfvSnlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6OzFpPkK4OFI3QTNzPD;hQi=>
T47D	NGLtfoVEgXSxdH;4bYNqfHliYYPzZZk>		MnTzOUBl[Xm\|	NUexcoY6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA2KGSjeYOsJGlEPTBiPTCwMlIyKM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh4NEmyPEc,OjN6NkS5Nlg9N2F-
Ishikawa endometrial cells	NIjaPFVHfW6ldHnvckBie3OjeR?=			MV7BcpRi\2:waYP0JIFkfGm4aYT5JIF{KGmwaHnibZRqd25ib3[gNUBvVSBzNz3i[ZRiNWW\|dILh[IlwdCC\|dHnteYxifGWmIHHsb4FtcW6nIIDoc5NxcGG2YYPlJIlv\HWldHnvckBqdiCLc3jpb4F4[SCnbnTvcYV1emmjbDDj[YxteyxiSVO1NEA:KDBwNUGg{txONg>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTN6MEKwPEc,OTV\|OECyNFg9N2F-
CV1	MlXOSpVv[3Srb36gZZN{[Xl?		NHjsOoQ1PSCqcoO=	M1TpSWlvfmW{c3WgZYdwdmm\|dDDhZ5Rqfmm2eTDheEBISUx2LVTORUBjcW6maX7nJIRwdWGrbj3meZNm\CCvb4Xz[UBGWlKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KEOYMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBz\WOncITvdkB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZYZ1\XJiNEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvPiEQvF2u	NFnxNJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG4PVM6Oyd-MkixPFk{QTN:L3G+
CV1	M4DXVmZ2dmO2aX;uJIF{e2G7		NIPDbII1PSCqcoO=	MWjJcpZmenOnIHHnc45qe3RiYXP0bZZqfHliYYSgS2FNPC2GTlGgZolv\GmwZzDkc41icW5vZoXz[YQhcHWvYX6gSXJT[mW2YTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDy[YNmeHSxcjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYX\0[ZIhPDViaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuOlUh\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6OUO5N{c,OjhzOEmzPVM9N2F-
HEK293	NHS1fIpHfW6ldHnvckBie3OjeR?=			MoP1RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDld5Rzd2enbjDy[YxifGWmIILlZ4VxfG:{IHfhcY1iKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNU4{PSEQvF2u	MnyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEW2PFgoRjJ3M{C1Olg5RC:jPh?=
MCF7	NWLL[IJwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkjtOFghcHK\|	NWjvNZFZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4Ppcoch\XO2cn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE4xODNibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlAyKG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW\|ZX7j[UBw\iB3JTDm[ZRidCCkb4\pcoUhe2W{dX2sJGdKPTBiPTCxMlQyOjV2IN88UU4>	M36xUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	M4KzNGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXO0PEBpenN?	M4nib2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDlfJBz\XO\|aX7nJIV{fHKxZ3XuJJJm[2WydH;yJIlv[3WkYYTl[EB4cXSqIECuNFYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVAhRSBzLkmwOVQ3KM7:TT6=	Ml7pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
HeLa	NUnvfmUzTnWwY4Tpc44h[XO\|YYm=		NIX5fXU1NjViaILz	MnOyTY5pcWKrdHnvckBw\iCHYn;sZZZqenW\|IHfsfYNweHKxdHXpck9u[XS{aYigdJJwfGWrbjDWVFQxKGWwdIL5JIlvKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOE42KGi{czDi[ZRiNWyjY4ThcYF{\SC{ZYDvdpRmeiCjc4PhfUwhUUN3MDC9JFEvQTZizszNMi=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ{NEO4O{c,Ojl4MkSzPFc9N2F-
MDA-MB-231	NUPtdINzS3m2b4TvfIlkcXS7IHHzd4F6		NYLBR4dHPCCmYYnz	NWPLXYZOS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyC2cnXheIVlKGW4ZYL5JFIh\GG7czDmc5IhPCCmYYnzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDJwNTFOwG0v	NFvkSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	NWK4dYRJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kd3Kyb4LheIlwdiCxZjDbcYV1cHmuLUPIYZRpgW2rZHnu[UBqdnSxIHPlcIx2dGG{IFTORUBqdiC\|ZYL1cUBnemWnIH3l[Il2dSCrbjDpckBi[nOnbnPlJI9nKDZwMjD1[{9uVCCUTnHz[UAyNCCLQ{WwJF0hOi55IN88UU4>	M2HtflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkGxOFc5Lz5{Mk[xNVQ4QDxxYU6=
MCF7	NXj1OWhDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUnsOVJ4PzJiaILz	MmDzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{Lke5JO69VS5?	NX;QPXlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PVY4ODZpPkK2PFk3PzB4PD;hQi=>
MCF12A	NUm4XVNtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXjwT5RKPDhiaILz	NUL3cWNpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFExOCCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFchdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKG[ndHHsJIJwfmmwZTDz[ZJ2dSCjbnSgUpVU\XK3bTygS2k2OCB;IEOuNlM2QTRizszNMi=>	NVnmNFl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF7	NITGUYFEgXSxdH;4bYNqfHliYYPzZZk>		NIDDU3E1KGSjeYO=	NVziNI5bS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgdI9{cXSrdnWgbJVu[W5iTVPGO{Bk\WyuczD0doVifGWmIHX2[ZJ6KDJiZHH5d{Bnd3JiNDDkZZl{KG2nYYP1doVlKGGodHXyJFch\GG7czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IEOuN{DPxE1w	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF12A	Mn3JRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFvZSFc1QCCqcoO=	NIXRdZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIV{fHKxZ3XuJJJm[2WydH;yMYRm\mmlaXXueEBpfW2jbjDNR2YyOkFiY3XscJMhcW6ldXLheIVlKHerdHigNE4xODNibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlAyKG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW\|ZX7j[UBw\iB3JTDm[ZRidCCkb4\pcoUhe2W{dX2sJGdKPTBiPTCzMlMyOTNzIN88UU4>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
MCF7	M{jITWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml6xOFghcHK\|	MkLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHX4dJJme3Orbneg[ZN1em:pZX6gdoVk\XC2b4KgbY5kfWKjdHXkJJdqfGhiMUCwJI5OKG:oIHXzeJJi\GmxbDDhcoQhOC5yNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZkhcW5icILld4Vv[2Vib3[g[oV1[WxiYn;2bY5mKHOncoXtJIFv\CCQdWPldpVuNCCJSUWwJF0hOy52NkezO{DPxE1w	M{DZPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MDA-MB-231	NX;2OY1LS3m2b4TvfIlkcXS7IHHzd4F6		NIPa[VA1KGSjeYO=	Mn22R5l1d3SxeHnjbZR6KGGpYXnud5QhTVJibnXnZZRqfmViaIXtZY4hVUSDLV3CMVI{OSClZXzsd{B1emWjdHXkJIV3\XK7IEKg[IF6eyCob4KgOEBl[Xm\|IH3lZZN2emWmIIDvd5QhdGG\|dDDkc5NmKGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOy53IN88UU4>	NHrkXGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF12A	M37lU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHvjRo01QCCqcoO=	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCPQ1[xNmEh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDNwOEmwOFUh\|ryPLh?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
MCF7	M372WmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3TRZ\|Qh\GG7cx?=	MoHzR5l1d3SxeHnjbZR6KGGpYXnud5QhTVJicH;zbZRqfmViaIXtZY4hVUOINzDj[YxteyC2cnXheIVlKGW4ZYL5JFIh\GG7czDmc5IhPCCmYYnzJI1m[XO3cnXkJJBwe3RibHHzeEBld3OnIHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iMz65JO69VS5?	M4LxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	M1jVUGZ2dmO2aX;uJIF{e2G7			MlvxTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gUWNHNTdiY3XscJMhcW5icILld4Vv[2Vib3[gNVBmNTZiTTDjc45k\W62cnH0bY9vKG:oIGuzTH0uKGW\|dILh[IlwdCBqRUKpMEBKSzNyIE2gOEDPxE1w	NXPadIM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2PVY5OSd-Mke2PVY5OTxxYU6=
MCF10A	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		NGXJ[Gs1KGSjeYO=	NVHpTZliS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVPGNVBCKGOnbHzzJJRz\WG2ZXSg[ZZmenliMjDkZZl{KG[xcjC0JIRigXNibXXhd5Vz\WRicH;zeEBt[XO2IHTvd4Uh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUA1KM7:TT6=	M1LNOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF10A	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		MlyzOEBl[Xm\|	MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCwZXfheIl3\SCqdX3hckBOS0ZzMFGgZ4VtdHNidILlZZRm\CCndnXyfUAzKGSjeYOg[o9zKDRiZHH5d{Bu\WG\|dYLl[EBi\nSncjC3JIRigXNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSB2IN88UU4>	NH;DTJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
yeast cells	M{O0O2FvfGmnc4Tyc4dmdmmlIHHzd4F6			NVLPSHVbSW62aXXzeJJw\2WwaXOgZYN1cX[rdImgZZQh\XO2cn;n[Y4hemWlZYD0c5Ih[WyyaHGg[ZhxemW\|c3XkJIlvKHmnYYP0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiMUetZoV1[S2nc4TyZYRqd2xvaX7keYNm\CCkZYThMYdidGGldH;zbYRie2ViYXP0bZZqfHliYomgeJdwKGi7YoLp[EBie3OjeTygTWM2OCB;IESuOEDPxE1w	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR2MUC4Okc,OTZ2NEGwPFY9N2F-
NCI-ADR-RES	NHnHcWJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVy0PEBpenN?	NXTBdol[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUmNKNUGGUj3SSXMh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wNFMhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkCxJI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kA2LSCoZYThcEBjd3[rbnWgd4VzfW1uIFfJOVAhRSB2LkS2Olg1KM7:TT6=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
BT-20	NXTQSWw5TnWwY4Tpc44h[XO\|YYm=	M3HKV\|ExKM7:TR?=		MlXsTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JJBzd2yrZnXyZZRqd25ib3[gRnQuOjBiY3XscJMhcW5icILld4Vv[2Vib3[gWHBGKGG2IEGw[U02KE1iY3;uZ4VvfHKjdHnvckwhUUN\|MDC9JFQvQCEQvF2u	MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OU[4NUc,Ojd4OU[4NVww[T5?
Calu-1	M3;BfGZ2dmO2aX;uJIF{e2G7		NWfOPG1mOzBibXnudy=>	NITHdJBKdmirYnn0bY9vKG:oIGDMSFEhcW5iaIXtZY4hS2GudT2xJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbIF1cWS7bHL1eIFvd2xvW3S5YUBxem:mdXP0bY9vKGGodHXyJFMxKG2rboOgZpkhdWG\|czDzdIVkfHKxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hPC56IN88UU4>	NF3IOVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGzOlk4PSd-MUmxN\|Y6PzV:L3G+
MCF7	NXzwTWh7TnWwY4Tpc44h[XO\|YYm=			NGKzcWdCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFicnXj[ZB1d3JiaX6gbJVu[W5iTVPGO{Bk\WyuczygTWM2OCB;IESuPFk4PzlizszNMi=>	NYPlWHh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NFcxOTJpPkK2OFA4ODF{PD;hQi=>
MDA-MB-231	NGm5W\|ZCdnSrY3HuZ4VzKGG\|c3H5		Mn7lOFghcHK\|	MUfBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNT60JO69VS5?	M{PhcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NVQ2Lz5{NEm0OlE1PTxxYU6=
MCF-7	M{TSbWN6fG:2b4jpZ4l1gSCjc4PhfS=>			NI\XRnlEgXSxdH;4bYNqfHliYXfhbY5{fCCPQ1[tO{Bk\WyuczDpckB1cGViYXLz[Y5k\SCxZjCxJJVOKEV{IDjld5Rz[WSrb3ypMEBEgXSxdH;4bYNqfHliPTC2JO69VS5?	NHvQV\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97MEi5N\|MzLz57MEi5N\|MzRC:jPh?=
NCI-ADR-RES	M1P5eWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIXRfYo1QCCqcoO=	NVHxNIxTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUmNKNUGGUj3SSXMh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDZwMU[1PVUh\|ryPLh?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
AU565	M2fx[2FvfGmlYX7j[ZIh[XO\|YYm=		M4HwWVQ5KGi{cx?=	NWGxN4RXSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNW6nZ3H0bZZmKEGXNU[1JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB4LkKg{txONg>?	M4flPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NVQ2Lz5{NEm0OlE1PTxxYU6=
MCF7L	M{HLc2FvfGmlYX7j[ZIh[XO\|YYm=		NFnk[Gw1QCCqcoO=	MVvBcpRq[2GwY3XyJIFo[Wmwc4SgbJVu[W5iRWKtdI9{cXSrdnWgUWNHP0xiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvOyEQvF2u	M2\uWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NVQ2Lz5{NEm0OlE1PTxxYU6=
SKOV3-MDR1-M6/6	MX7BcpRq[2GwY3XyJIF{e2G7		NF;wVlQ1QCCqcoO=	M{fKc2FvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDTT29XOy2PRGKxMW03NzZiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvPDlizszNMi=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF7	NXfUV5NDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXuyOEBpenN?	NH;2RpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEeuNkDPxE1w	M4Th[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi5NFU2Lz5{NEG4PVA2PTxxYU6=
SKOV3	MnTJRY51cWOjbnPldkBie3OjeR?=		MYC0PEBpenN?	M1vKXWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDQMYdxKGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA4NjR4IN88UU4>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
PC3	M3PyUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXe0PEBpenN?	NYnkbXFqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBidmS{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gVGM{KGOnbHzzJIlv[3WkYYTl[EB4cXSqIECuOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUA4NjV6NUe4JO69VS5?	NHTn[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
NCI-ADR-RES	NGPKRpBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH;YT5A1QCCqcoO=	NWjvfWQ3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUmNKNUGGUj3SSXMh[2WubIOgbY5kfWKjdHXkJJdqfGhiMUCwJI5OKG:oIHXzeJJi\GmxbDDhcoQhOC5yNzDuUUBw\iC2ZYP0c5N1\XKxbnWgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZkhcW5icILld4Vv[2Vib3[g[oV1[WxiYn;2bY5mKHOncoXtJIFv\CCQdWPldpVuNCCJSUWwJF0hPy55NkK0O{DPxE1w	MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MCF-7	M{THUWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MoHwR5l1d3O2YYTpZ4l1gSCjZ3HpcpN1KE2FRj23JINmdGy\|IHnuJJRp\SCycnXz[Y5k\SCxZjCxJJVOd2yjcjDFNkAp\XO2cnHkbY9tMSxiSVO1NEA:KDhizszNMi=>	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTB6OUOzNkc,QTB6OUOzNlww[T5?
LNCAP	NFTzfINCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3ewUVQ5KGi{cx?=	NFqx[HpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIV5eHKnc4Ppcoch[W6mcn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE43KG6PIH;mJIV{fHKjZHnvcEBidmRiMD63JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDhwM{G3OlQh\|ryPLh?=	NGLD[2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
MCF7	NVfvfXZ1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2DGN\|Uh\GG7cx?=	NVTUN4hFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDXV3QuQCCjc4PhfUwhUUN3MDC9JFgvQSEQvF2u	NHX0NmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[xOFEyQCd-MkW2NVQyOTh:L3G+
MCF7	NUXTOJhZSW62aXPhcoNmeiCjc4PhfS=>		MUS0PEBpenN?	NXXRemdPSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDlwMjFOwG0v	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF-7	NUnrOmdsS3m2b4TvfIlkcXS7IHHzd4F6			M4LGU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2FRj23JINmdGy\|IHnuJJBz\XOnbnPlJI9nKDFidV2gSVIhMGW\|dILh[IlwdCluIFP5eI91d3irY3n0fUA:KDlwNDFOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86ODh7M{OyK\|46ODh7M{OyQE9iRg>?
MDA-MB-231	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHX4doEzPCCqcoO=	NV2yV\|diSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzMD60JO69VS5?	M1\ueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUi5NFU2Lz5{NEG4PVA2PTxxYU6=
MDA-MB-453	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVTEVHpLPzJiaILz	NGW5N4RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFyLkSg{txONg>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyNkW4Nkc,Ojh3ME[1PFI9N2F-
DU145	NITmXINCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnjBOFghcHK\|	NVPT[HhiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBidmS{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gSHUyPDViY3XscJMhcW6ldXLheIVlKHerdHigNE43KG6PIH;mJIV{fHKjZHnvcEBidmRiMD63JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDFyLkexOVIh\|ryPLh?=	M4Gzc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	NF7nRVJEgXSxdH;4bYNqfHliYYPzZZk>		MUi0PEBpenN?	MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxN{43KM7:TT6=	NWfvXpQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NVg2QTVpPkK1OlE5PTl3PD;hQi=>
Vero	NYHORYdNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NF\EXZc4OiCqcoO=	NUHwO48zSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBi\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE2NjFizszNMi=>	M3rx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUmzNlY6Lz5{NUm5N\|I3QTxxYU6=
DU145	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYq3NkBpenN?	M3TmbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTVwMzFOwG0v	M1HCd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUmzNlY6Lz5{NUm5N\|I3QTxxYU6=
MCF7	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1vobFczKGi{cx?=	MlLDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzNT62JO69VS5?	NUfoRZp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFY2QDJpPkK4OVA3PTh{PD;hQi=>
MCF7	NInFRVRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWK3NkBpenN?	NGjZbG5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTVwNjFOwG0v	NYjCfFNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVMzPjlpPkK1PVk{OjZ7PD;hQi=>
MDA-MB-231	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHu4WHE4OiCqcoO=	NWXlZ4RMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{MD6xJO69VS5?	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3ME[1PFIoRjJ6NUC2OVgzRC:jPh?=
MCF7	MoK3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NEPHSVgxNjZ{NTDuUS=>	MoH6NlQhcHK\|	M3jzXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDheEAxNjZ{NTDuUUBi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5MkK1Okc,OTh{N{KyOVY9N2F-
MCF7	M4XYOWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MmjlNE43OjVidH:gNVAhdk1?	MknDNlQhcHK\|	NVvFPHpHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF1KD5yLk[yOUB1dyBzMDDuUUBi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5	NH;4UJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3NlI2Pid-MUiyO\|IzPTZ:L3G+
MCF7:WS8	MXfGeY5kfGmxbjDhd5NigQ>?			MlLSRYN1cX[jdHnvckBw\iCqdX3hckBGWiCrbjDoeY1idiCPQ1[3PndUQCClZXzsd{BmgHC{ZYPzbY5oKGW\|dILv[4VvKHKnc4DvcpNqfmViZXzlcYVvfCCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|M{SzOlgoRjJyM{O0N\|Y5RC:jPh?=
MCF7:WS8	M1njfGFvfGmnc4Tyc4dmdmmlIHHzd4F6	NH;KdIMyKHWP	MV:3JIRigXN?	MofnRY51cWW\|dILv[4VvcWNiYXP0bZZqfHliaX6gbJVu[W5iRWLhcJBp[SCneIDy[ZN{cW6pIF3DSlc7X1N6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDheEAyKHWPIHHmeIVzKDdiZHH5dy=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MCF7	Mof2RY51cWW\|dILv[4VvcWNiYYPzZZk>			MUnBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLYP0bY12dGG2ZXSgdJJwdGGldHnuJIdmdmViZYjwdoV{e2mxbh?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MCF7	MXPBcpRq\XO2cn;n[Y5q[yCjc4PhfS=>			NHrkUotCdnSrZYP0do9o\W6rYzDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[g[ZN1emGmaX;sMZN1cW23bHH0[YQheHKxbHnm[ZJifGmxbh?=	NX7TXXdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
T47D:C:4:2	NULUdFRJTnWwY4Tpc44h[XO\|YYm=			NI\peYdGe3S{b3flcolkKGGldHn2bZR6KGG2IIfpcIQhfHmyZTDFVkBidHCqYTDlfJBz\XO\|ZXSgbY4hXDR5RErDPlQ7OiClZXzsd{Bkd2W6cILld5NqdmdiZYP0do9o\W5icnXzdI9ve2ViZXzlcYVvfCCkeTDkeYVtKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?=	M3rGRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{O0N\|Y5Lz5{MEOzOFM3QDxxYU6=
MDA-MB-231	MlTTR5l1d3SxeHnjbZR6KGG\|c3H5		MXKzJIRigXN?	MmPYR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KG2rY4LveIl1\XJiYYPzZZk>	NYnlXnlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1PVg2PTVpPkKwOVk5PTV3PD;hQi=>
T47D:C:4:2	MVHGeY5kfGmxbjDhd5NigQ>?			Mn33SZN1em:pZX7pZ{Bi[3Srdnn0fUBifCC5aXzkJJR6eGViRWKgZYxxcGFiREO1NWchdXW2YX70JIV5eHKnc4Pl[EBqdiCWNEfEPmM7PDp{IHPlcIx{KGOxZYjwdoV{e2mwZzDld5Rzd2enbjDy[ZNxd26\|ZTDlcIVu\W62IHL5JIR2\WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NH\oZ4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOzOFM3QCd-MkCzN\|Q{Pjh:L3G+
MCF7	MmnUSpVv[3Srb36gZZN{[Xl?	MVmxJO69VQ>?	NHXuSnI3KGSjeYO=	M2LmUmRzfWdidYD0ZYtmKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAoNTZiTTDh[pRmeiB4IHThfZMh[nliSGDMR{1OWy:PUzDhcoFtgXOrcx?=	Mkj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NkS5NlgoRjJ\|OE[0PVI5RC:jPh?=
MCF7	NHLZcWpHfW6ldHnvckBie3OjeR?=	NYr4bIVyOTBidV2=	MoTrOkBpenN?	MYPVdJJm\3WuYYTpc44hd2ZiRWLhcJBp[SCycn;0[YlvKGyndnXsd{BqdiCqdX3hckBOS0Z5IHPlcIx{KGG2IEGwJJVOKGGodHXyJFYhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	MkXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{K2N\|AoRjJ2M{OyOlMxRC:jPh?=
MCF7:WS8	NHTyXYVHfW6ldHnvckBie3OjeR?=	M33EbVEh\|ryP	MorrOFghcHK\|	NVe3d5BDSWexbnnzeEBi[3Srdnn0fUBifCCHUjDpckBpfW2jbjDNR2Y4QleVODDj[YxteyCjc4Pld5Nm\CCjczDwV\|Ih\2WwZTDlfJBz\XO\|aX;uJIF1KDFyJz22JG0h[W[2ZYKgOFghcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	M2racFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1NVk6Lz5{NEiwOVE6QTxxYU6=
MCF7:WS8	NYO1e\|JiTnWwY4Tpc44h[XO\|YYm=	M3j1SVEh\|ryP	MUm0PEBpenN?	M2\LTmFod26rc4SgZYN1cX[rdImgZZQhTVJiaX6gbJVu[W5iTVPGO\|pYWzhiY3XscJMh[XO\|ZYPz[YQh[XNiR2LFRlEh\2WwZTDlfJBz\XO\|aX;uJIF1KDFyJz22JG0h[W[2ZYKgOFghcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	M2LpfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1NVk6Lz5{NEiwOVE6QTxxYU6=
GH3	NVjYUZBYTnWwY4Tpc44h[XO\|YYm=	NIrnVmQyKM7:TR?=	MXG0PEBpenN?	M3;xfGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTZiTTDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{	NETofFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
GH3	NHjhTZZHfW6ldHnvckBie3OjeR?=	MoPSNE4yKG6PIITvJFEh\|ryP	MnnnOFghcHK\|	NFrzV2dCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSJIlvKHKjdDDHTFMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDld5Rz[WSrb3ytbY5lfWOnZDDwdo9t[WO2aX6g[4Vv\SCneIDy[ZN{cW:wIHH0JFExLy1zMDD0c{AyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	NVzhOW1URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFUyQTlpPkK0PFA2OTl7PD;hQi=>
MCF7	M4D1fWFvfGmlYX7j[ZIh[XO\|YYm=	NVL3UWhwOjVyIITvJFUxOCCwTR?=	NUmyOIE4PSCmYYnz	NUjSR4plSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCnc4TyZYRqd2xvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlUxKHSxIEWwNEBvVSCjZoTldkA2KGSjeYO=	NGnpU3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlE1PSd-MkS5OFYyPDV:L3G+
MCF7	NHT0cWVHfW6ldHnvckBie3OjeR?=	NXfRSodLPSC3TR?=	MU[yOEBpenN?	NVH4W2R4SW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gUXlEKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	NGPKZXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	M4LyXWZ2dmO2aX;uJIF{e2G7	NU\RUXBwPSC3TR?=	Mnf6NlQhcHK\|	NUTGRXFzSW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gWGZHOSCvUl7BJIV5eHKnc4Ppc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgVWlCgm:uIILlZYdmdnRiYnHz[YQhWlRvcWDDVkBidmGueYPpdy=>	M4DCUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	MmDoSpVv[3Srb36gZZN{[Xl?	NF7Ce\|U2KHWP	Mny0NlQhcHK\|	M1[w[2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWLhcJBp[SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIFfSSWIyKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	NUPQPVdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	MXPGeY5kfGmxbjDhd5NigQ>?	MnK0OUB2VQ>?	NU\ESIt3OjRiaILz	MmO5RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiTWnCUFIhdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	NF;Pcos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
MCF7	NVLsTlZITnWwY4Tpc44h[XO\|YYm=	NHHCR2Q2KHWP	NX7DdWo5OjRiaILz	NEDQWpRCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDDR25FOSCvUl7BJIV5eHKnc4Ppc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgVWlCgm:uIILlZYdmdnRiYnHz[YQhWlRvcWDDVkBidmGueYPpdy=>	NUTPXYlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	MVvGeY5kfGmxbjDhd5NigQ>?	MoK2OUB2VQ>?	NWrJd\|U{OjRiaILz	Mle5RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQ1TDOkBuWk6DIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliUVnBfo9tKHKnYXflcpQh[mG\|ZXSgVnQueVCFUjDhcoFtgXOrcx?=	Ml;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	M3fVPGZ2dmO2aX;uJIF{e2G7	Mmj6OUB2VQ>?	NEPXSFQzPCCqcoO=	NE\zU5FCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDFNmYyKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	NV75OpRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	M2HKTmZ2dmO2aX;uJIF{e2G7	NYjM[5RpPSC3TR?=	MmT3NlQhcHK\|	MkfORY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiTVvJOlchdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	NVT2RoFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; PubMed: 26163823 Cell Signal LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2.	26163823
Growth inhibition assay	Cell viability; PubMed: 26014809 Eur J Nutr Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.	26014809

Protocol

Cell Research: ^[1]	- Collapse Cell lines: Adult Rat and Mouse Cardiac Myocytes Concentrations: 0, 0.5, 1, 3, 5, and 10 µM Incubation Time: 15-45 min Method: For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 21 mg/kg, 54 μmol/kg Administration: oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	77 mg/mL (198.7 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Hydroxytamoxifen(Afimoxifene) SDF

Molecular Weight	387.51
Formula	C₂₆H₂₉NO₂
CAS No.	68392-35-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Afimoxifene
Smiles	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03199963	Terminated	Drug: 4-OH tamoxifen\|Drug: Placebo	Mammographic Breast Density	BHR Pharma LLC	August 21 2017	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Licochalcone A ^New

Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Fulvestrant

Fulvestrant (ICI-182780, ZD 9238) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Tamoxifen Citrate

Tamoxifen Citrate (ICI 46474) is a selective estrogen receptor modulator (SERM). Tamoxifen Citrate is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen induces apoptosis and autophagy.
Mifepristone

Mifepristone (RU486, C-1073) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.

Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.
Raloxifene HCl

Raloxifene (LY156758, Keoxifene) HCl a selective and orally active estrogen receptor modulator (SERM), which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.
Estradiol

Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
Toremifene Citrate

Toremifene Citrate (NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
Progesterone

Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Hydroxytamoxifen(Afimoxifene)